Medicines regulation and clinical pharmacology: Editors' view

British Journal of Clinical Pharmacology

Volumn 58, Issue 6, 2004, Pages 569-570

  Baber, N S ^a   Ritter, J M ^b   Aronson, J K ^c  

^a Medicines Hlthcare Prod R   (United Kingdom)

^b ST THOMAS HOSPITAL   (United Kingdom)

^c RADCLIFFE INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIHYPERTENSIVE AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CYCLOOXYGENASE 2 INHIBITOR; ROFECOXIB;

ANTIHYPERTENSIVE THERAPY; BODY WEIGHT DISORDER; CARDIOTOXICITY; CLINICAL PHARMACOLOGY; CONFERENCE PAPER; COST BENEFIT ANALYSIS; DRUG APPROVAL; DRUG CONTROL; DRUG DEVELOPMENT; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; HUMAN; MEDICAL TECHNOLOGY; PHARMACOGENOMICS; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; SIDE EFFECT; WEIGHT GAIN;

EID: 10844243182     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2004.02341.x     Document Type: Conference Paper

References (2)

1. US Food and Drug Administration. Challenge and opportunity on the critical path to new medical products. 2004. http://www.fda.gov/oc/initiatives/ criticalpath/whitepaper.html (accessed 22 October 2004)
2. Aronson JK. Live long and prosper: a mass strategy for treating the factors associated with ischaemic heart disease and stroke. J Med Screen 2004; 11: 1-2.